Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16

On August 21, 2024 Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, reported the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University’s Cancer Hospital (Press release, Everest Medicines, AUG 21, 2024, View Source [SID1234646041]). This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. EVM16CX01 is the first-in-human (FIH) trial for EVM16.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EVM16 is a novel personalized therapeutic mRNA cancer vaccine independently developed by Everest. EVM16 contains neoantigens with high immunogenicity potential that are predicted based on the unique tumor mutations of each patient by Everest’s proprietary neoantigen prediction algorithm. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.

"EVM16 is the first personalized mRNA cancer vaccine independently developed by Everest using our proprietary mRNA platform. The initiation of this clinical trial is an important milestone that demonstrates our commitment to discover and develop a new generation of mRNA immunotherapies for cancer and autoimmune diseases." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines."While establishing leadership positions in nephrology, infectious disease, and autoimmune diseases, Everest will also focus on innovative modalities such as therapeutic mRNA vaccines. We look forward to seeing personalized cancer vaccines become a new clinical treatment method to serve more patients."

According to the Globocan’s data in 2022, there were 19.976 million new cancer cases globally, with 9.744 million cancer-related deaths[1]. In the last few decades, Immunotherapy including checkpoint inhibitors has become an important part of treating some cancer types. However, they are only effective for some patients, and there is an urgent need to develop new generations of immunotherapies, such as personalized mRNA cancer vaccines, that have demonstrated early promise in clinical development.

In preclinical studies, vaccination with EVM16 stimulated a strong neoantigen-specific T cell response in different mouse models and showed significant tumor growth inhibition in the syngeneic B16F10 mouse melanoma model. Preclinical data also demonstrated that the combination of EVM16 and a PD-1 antibody has synergistic effect, which supports the clinical application of the combination of EVM16 with checkpoint inhibitors. In preclinical toxicity studies, repeated dosing with EVM16 was well tolerated and safe. Taken together, the preclinical immunogenicity, efficacy and safety studies demonstrate that EVM16 is safe and has potential to bring benefits to cancer patients.

Everest has built end-to-end capabilities across its proprietary mRNA platform. Our R&D team is developing multiple mRNA-based therapeutic products, as well as next generation lipid nanoparticle (LNP) delivery systems to enhance cell-mediated immune response. Our mRNA manufacturing facility in Jiashan, Zhejiang Province in China is designed to comply with global cGMP standards and is able to produce at clinical- and commercial-scale. Everest owns full global intellectual property rights to its mRNA therapeutic programs.

About EVM16

EVM16 is a novel personalized mRNA cancer vaccine independently developed by Everest Medicines Limited.. EVM16 contains neoantigens with high immunogenicity potential which are predicted by Everest-proprietary algorithm and uses an LNP delivery system to efficiently deliver mRNAs that express tumor neoantigens into the human body. After vaccination with EVM16, neoantigens-encoding mRNAs are delivered into cells to produce neoantigen peptides, which activate neoantigen-specific T cell immune responses to kill tumor cells, thereby inhibiting tumor growth

About EVM16CX01 study

The study is a FIH, dose escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and initial efficacy of EVM16 injection as a single and in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.,. The primary objectives are to evaluate the safety and tolerability of EVM16 monotherapy and EVM16 in combination withPD-1 antibody in subjects with advanced or recurrent solid tumors, and to determine the recommended phase 2 dose (RP2D) of EVM16. The secondary objectives are to evaluate the immunogenicity of EVM16, and the initial efficacy of EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

On August 21, 2024 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that management will participate in the following investor conferences in September (Press release, Bicycle Therapeutics, AUG 21, 2024, View Source [SID1234646025]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4; fireside chat at 8:30 a.m. ET
2024 Cantor Global Healthcare Conference on Wednesday, Sept. 18; fireside chat at 11:30 a.m. ET

Live webcasts of the fireside chats will be accessible in the Investor section of the company’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.

PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment

On August 21, 2024 PhotonPharma, a cutting-edge biopharmaceutical company based in Fort Collins, Colorado, is pleased to announce the successful closing of a $2.5 million seed financing round (Press release, PhotonPharma, AUG 21, 2024, View Source [SID1234646042]). This vital funding will support the Phase I clinical trial of Innocell, an innovative therapy for the treatment of advanced ovarian cancer. According to the National Cancer Institute (View Source) ovarian cancer will impact 19,680 women in the US with 12,740 deaths in 2024 alone. The average five-year relative survival rate is 50.4% (2014-2020).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In February 2024, PhotonPharma received FDA clearance to initiate clinical development of Innocell. The Phase I trial, expected to enroll its first patient in Q4 2024, will be a crucial step in evaluating the safety and efficacy of this promising new treatment.

"This funding is a significant milestone for PhotonPharma and marks a pivotal moment in our mission to advance breakthrough therapies for cancer therapies," said Dr. Terry Opgenorth, Chairman of the Board of Directors of PhotonPharma. "We are excited to move forward with our clinical trials and are grateful for the support of our investors, whose confidence will help drive the development of our technology platform forward."

PhotonPharma’s presentation at the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference will provide a comprehensive overview of the company’s progress and development plans. The conference will be an opportunity for investors and partners to learn more about PhotonPharma’s advancements and the potential impact of Innocell on the treatment of ovarian cancer.

Founded in 2018, PhotonPharma is dedicated to pioneering novel drug delivery systems and targeted treatments aimed at improving cancer care. The company’s innovative approach and commitment to scientific excellence position it at the forefront of cancer therapeutics.

"We invite investors and industry partners to attend our presentation at the Rocky Mountain Life Sciences Investor and Partnering Conference in September," added Dr. Alan Rudolph, CEO of PhotonPharma. "It’s an excellent opportunity to learn about the development of our cutting-edge technology and the development plans for the company and its technology platform."

Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer

On August 21, 2024 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported a strategic repositioning for VB10.16, a potentially first-in-class off-the-shelf therapeutic DNA-based cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers (Press release, Nykode Therapeutics, AUG 21, 2024, View Source [SID1234646010]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the strategic repositioning, the company has decided to focus the development of VB10.16 on locally advanced cervical cancer and recurrent metastatic head and neck cancer. This decision follows a comprehensive strategic review, which considered the timing of development activities, the need to optimize financial and human resources, and positive feedback from key opinion leaders, alongside input from potential future partners.

Recent changes in standard-of-care has extended the timelines for the C-04 trial, diminishing its viability as a fast-to-market strategy. In light of this, Nykode has decided to discontinue the C-04 trial to concentrate the company’s financial and human resources on more promising indications. The decision is expected to reduce the VB10.16 development costs by over $25 million, which combined with our planned partnering strategy, will substantially extend the company’s cash runway.

Michael Engsig, Chief Executive Officer of Nykode Therapeutics, stated: "The decision to focus on locally advanced cervical cancer and recurrent metastatic head and neck, and discontinue the C-04 trial in 2L cervical cancer, is part of our strategic repositioning to concentrate resources on the most commercially promising areas where we create significant benefits for patients in need, while generating value for shareholders. We remain highly enthusiastic about the broad potential of VB10.16 to make a meaningful difference in the lives of patients with HPV-driven cancers. While we regret the impact of excluding 2L cervical cancer from our immediate pipeline, we are eager to advance VB10.16 where we see the highest likelihood of clinical efficacy and the greatest market potential.

Klaus Edvardsen, Chief Research & Development Officer of Nykode Therapeutics, added: "Our commitment to developing VB10.16 as a treatment option for patients with HPV-driven cancers remains strong. To focus our efforts on indications with the clearest path to registration, we have decided to discontinue our work on recurrent/metastatic cervical cancer to concentrate on locally advanced cervical cancer, which is supported by the C-02 data demonstrating the vaccine’s capability of deepening responses and maintaining clinical benefit for a prolonged period. We extend our gratitude to the partners involved in developing the C-04 trial and look forward to continuing our work on VB10.16."

About VB10.16

VB10.16 is a potentially first-in-class off-the-shelf therapeutic DNA-based cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers. The cancer vaccine is designed based on Nykode’s Vaccibody technology platform of targeting antigens to antigen presenting cells. VB10.16 has reported promising data from a Phase 2 trial in advanced PD-L1 positive cervical cancer patients (NCT04405349) in combination with atezolizumab with mOS not reached, but at least 24 months at the time of analysis. The vaccine-induced significant HPV16-specific T cell responses that were correlated with clinical responses. The candidate has also demonstrated favorable clinical data in a Phase 1/2a study in pre-cancerous HPV16-induced high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) demonstrating a statistically significant correlation of immune responses and clinical responses. Nykode is currently investigating VB10.16 in VB-C-03, an open-label, dose-finding Phase 1/2a trial evaluating VB10.16 in combination with MSD’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with HPV16-positive, PD-L1-positive, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC).

About Cervical Cancer

Cervical cancer is the fourth leading cause of cancer death in women worldwide and is most frequently diagnosed between the ages of 35 and 44. Each year around 600,000 women are diagnosed with cervical cancer worldwide. Almost all cases are caused by human papillomavirus (HPV) infection and HPV16 accounts for more than half of all cervical cancer cases. Approximately 80% of patients with cervical cancer have squamous cell carcinoma and most other patients have adenocarcinomas. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced disease stages or when the cancer has spread.

About Head & Neck Cancer

The number of patients with squamos cell head and neck cancer (HNSCC) has risen substantially during the last decades and around 660,000 patients globally are now diagnosed yearly. This rise in incidence in HNSCC is mainly attributable to HPV infections. HPV 16 accounts for nearly 90% of such cases. HNSCC can be managed effectively in early stages, however, most patients are diagnosed at advanced stages where treatment outcomes are less favorable.

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors

On August 21, 2024 Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, reported an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company’s ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia (AML) (Press release, Bio-Path Holdings, AUG 21, 2024, View Source [SID1234646026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These positive responses mark a significant milestone for Bio-Path as they suggest our DNAbilize platform technology has the potential to produce multiple drug candidates capable of targetspecific protein inhibition for over-expressed, disease-causing gene products," said Peter H. Nielsen, President and Chief Executive Officer of Bio-Path. "We were thrilled to see that our first patient treated with the higher dose (90 mg/m2) in our Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. We believe this is significant, particularly considering the heavily pretreated and fragile patient population involved."

"This elderly female patient with gynecologic cancer had previously been treated with multiple lines of chemotherapy along with multiple surgeries for her disease, and only now is showing positive clinical results with BP1001-A treatment. Importantly, we are not seeing the onerous side effects typically seen in patients with advanced solid tumors being treated with standard frontline therapies," continued Mr. Nielsen.

"In addition, we observed extended treatment durability in two elderly patients in our Phase 2 triple combination study of prexigebersen, venetoclax and decitabine in AML patients. These ongoing positive outcomes underscore the potential for prexigebersen to treat fragile AML patients for extended periods. We are particularly pleased with these results, as AML patients are typically unable to tolerate intensive chemotherapy and thus experience very poor clinical outcomes," concluded Mr. Nielsen.

Bio-Path’s DNAbilize Technology Platform – Bio-Path’s DNAbilize platform is a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Bio-Path believes this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, DNAbilize delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, the Company’s DNAbilize drug candidates have demonstrated a promising safety and efficacy profile. Bio-Path currently has four DNAbilize drug product candidates in development.

Solid Tumor Patient Response in Second, Higher Dose Cohort – Bio-Path’s first patient in the second dose cohort in its Phase 1/1b advanced solid tumor clinical trial experiencing a positive response may signal that this analog of prexigebersen has potential as a new treatment for advanced solid tumors. The patient appears to be doing well on study after failing extensive chemotherapy and surgical treatment for gynecologic cancer, demonstrating a 15% reduction in her primary tumor through six cycles of treatment. Moreover, it appears that these positive outcomes may have contributed to allow her to continue with rigorous exercise and improved quality of life.

The dose finding portion of the Phase 1/1b trial is comprised of BP1001-A monotherapy with no accompanying chemotherapy. This clinical trial of BP1001-A in patients with advanced or recurrent solid tumors has successfully completed the initial prescribed dose in the first cohort of 60 mg/m2 and began enrollment in the higher dose cohort of 90 mg/m2. The Phase 1b portion of the study is expected to commence after completion of three planned BP1001-A monotherapy dose level cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors. Phase 1b studies are also expected to be opened in combination with gemcitabine in late-stage pancreatic cancer

AML Patients Demonstrate Extended Treatment Durability – During the Company’s recent pause for an interim analysis of results for Bio-Path’s Phase 2 clinical trial treating AML patients, attention focused on two elderly patients who demonstrated continued treatment durability. The first patient is an elderly female who has received 16 cycles of treatment over 21 months and continues in complete remission. The second patient is an elderly male who is completing his twelfth cycle of treatment over fourteen months and continues in complete remission. The clinical trial investigator treating these two patients indicated that they are both doing very well on treatment. Both patients are being treated with the triple combination of prexigebersen, decitabine and venetoclax.